• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    5/24/23 9:06:56 AM ET
    $APGN
    $BDRX
    $BIOC
    $CWBR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APGN alert in real time by email

    Gainers

    • Minerva Surgical (NASDAQ:UTRS) stock moved upwards by 213.3% to $0.57 during Wednesday's pre-market session. The company's market cap stands at $100.8 million.
    • Apexigen (NASDAQ:APGN) stock rose 40.1% to $0.56. The company's market cap stands at $13.8 million.
    • Enveric Biosciences (NASDAQ:ENVB) shares increased by 33.65% to $4.21. The market value of their outstanding shares is at $8.7 million.
    • Zura Bio (NASDAQ:ZURA) stock moved upwards by 23.55% to $6.61. The market value of their outstanding shares is at $210.2 million.
    • vTv Therapeutics (NASDAQ:VTVT) shares moved upwards by 22.14% to $1.07. The company's market cap stands at $87.1 million.
    • Immutep (NASDAQ:IMMP) stock increased by 15.65% to $2.66. The company's market cap stands at $233.8 million.

    Losers

    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock fell 24.1% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $2.8 million.
    • Ocugen (NASDAQ:OCGN) stock decreased by 23.5% to $0.55. The company's market cap stands at $124.5 million.
    • CohBar (NASDAQ:CWBR) stock declined by 22.16% to $3.9. The market value of their outstanding shares is at $11.3 million.
    • PTC Therapeutics (NASDAQ:PTCT) stock declined by 19.88% to $46.8. The company's market cap stands at $3.4 billion.
    • Biocept (NASDAQ:BIOC) stock declined by 13.69% to $4.48. The company's market cap stands at $2.6 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) stock fell 13.25% to $1.31. The market value of their outstanding shares is at $17.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGN
    $BDRX
    $BIOC
    $CWBR

    CompanyDatePrice TargetRatingAnalyst
    Ocugen Inc.
    $OCGN
    3/17/2026$12.00Buy
    Canaccord Genuity
    Immutep Limited
    $IMMP
    3/13/2026Buy → Hold
    Maxim Group
    Immutep Limited
    $IMMP
    3/13/2026$1.00Outperform → Neutral
    Robert W. Baird
    Immutep Limited
    $IMMP
    3/13/2026Mkt Outperform → Mkt Perform
    Citizens
    vTv Therapeutics Inc.
    $VTVT
    3/12/2026$44.00Outperform
    Evercore ISI
    Ocugen Inc.
    $OCGN
    3/11/2026$10.00Outperform
    Oppenheimer
    Immutep Limited
    $IMMP
    2/17/2026$6.00Mkt Outperform
    Citizens
    Zura Bio Limited
    $ZURA
    2/9/2026$15.00Outperform
    Wedbush
    More analyst ratings

    $APGN
    $BDRX
    $BIOC
    $CWBR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Ocugen with a new price target

    Canaccord Genuity initiated coverage of Ocugen with a rating of Buy and set a new price target of $12.00

    3/17/26 8:33:47 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immutep downgraded by Maxim Group

    Maxim Group downgraded Immutep from Buy to Hold

    3/13/26 12:51:00 PM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immutep downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Immutep from Outperform to Neutral and set a new price target of $1.00

    3/13/26 8:45:21 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $BDRX
    $BIOC
    $CWBR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $APGN
    $BDRX
    $BIOC
    $CWBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

    3/18/26 9:30:18 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

    3/18/26 9:30:20 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

    3/18/26 9:30:15 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $BDRX
    $BIOC
    $CWBR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ADR Ratio Change

    March 18, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing one hundred thousand (100,000) ordinary shares, to the new ratio of one (1) ADR representing five hundred thousand (500,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be on or about April 6, 2026. Pursuant to the Ratio Change, ADR holders will be required on a

    3/18/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Announces Registration of Five Trademarks

    Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the Canadian Intellectual Property Office has registered five of the Company's trademarks, including its house marks, Enveric and Enveric Biosciences. "The registration of a Company's house marks, such as our marks Enveric and Enveric Biosciences, is an important intellectual property milestone supporting our branding strategies for our future products. We thank the Canadian Intellectual Property

    3/18/26 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics to Participate in the 38th Annual ROTH Conference

    HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in a fireside chat and conduct 1x1 investor meetings at the 38th Annual ROTH Conference, which is being held March 22-24, 2026, in Dana Point, CA. 38th Annual ROTH Conference:Format: Fireside chat and 1x1 investor meetingsDate:Monday, March 23, 2026Time: 10:00 AM PDTWebcast Link    A live webcast of the fireside chat will be available on the

    3/16/26 8:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $BDRX
    $BIOC
    $CWBR
    SEC Filings

    View All

    SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

    6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/18/26 5:11:41 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Immutep Limited

    6-K - IMMUTEP Ltd (0001506184) (Filer)

    3/16/26 6:01:29 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Shuttle Pharmaceuticals Holdings Inc.

    8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    3/10/26 5:00:43 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $BDRX
    $BIOC
    $CWBR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ai Biotechnology Llc bought $12,500,000 worth of Class A Ordinary Shares (2,000,000 units at $6.25) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    3/2/26 5:55:03 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    12/2/24 4:15:25 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    11/26/24 4:50:10 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BDRX
    $BIOC
    $CWBR
    Leadership Updates

    Live Leadership Updates

    View All

    vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026  Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and pro

    3/10/26 4:01:00 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

    2/23/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BDRX
    $BIOC
    $CWBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:52:59 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/14/24 5:22:11 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $BDRX
    $BIOC
    $CWBR
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    – Full-year 2025 product and royalty revenue of $831M, exceeding guidance –– Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively –– Cash of $1.95B as of December 31, 2025 –WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.  "We delivered another strong quarter and finish to 2025, building on the successful global launch of Sephience," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "With our robust commercial engine, innovative R&D programs,

    2/19/26 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec

    2/18/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

    WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's business and outlook on Thursday, Feb. 19, 2026, at 4:30 p.m. ET. To access the call by phone, please click here to register and you will be provided with dial-in details. The webcast conference call can be accessed on the Investors section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call w

    2/5/26 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care